Vascular Pathways Gets FDA Nod for AccuCath Midline Catheter System

Vascular Pathways has received U.S. Food and Drug Administration 510(k) clearance of its AccuCath 3.1-inch BC Midline Catheter and has launched the product in the United States. The device is meant to reach vasculature formerly thought to be too deep for traditional IV placement.

Developed as an option for patients with challenged peripheral vasculature whose hospital stay lasts 29 days or less and who don’t require a central line, the system includes a 3.1-inch injectable catheter, blood control valve and patented AccuTip coiled Nitinol guidewire.

The product’s design is intended to increase first-time success, reduce complication rates, extend dwell times, increase patient satisfaction and lower overall provider costs, the Boca Raton, Fla., company said in a brief news release.

“Our new AccuCath 3.1” BC Midline Catheter provides a clinical solution to DIVA (Difficult IV Access) patients whose stay will last 29 days or less and don’t require a central line,” President/CEO Bill Bold said. “It’s ergonomic design, increased length, and patented coiled-tip Nitinol guidewire are designed to access vasculature previously considered too deep for traditional IV placement.”

Founded in 2005 by Amir Belson, M.D., Vascular Pathways is a medical device company commercializing the AccuCath IV Catheter System line. The company is privately held by CHL Medical Partners, Ascension Health Ventures, and MVM Life Sciences.